CeriBell Set to Unveil Financial Results for 2024
CeriBell, Inc. (Nasdaq: CBLL) is gearing up for an important event that could significantly impact investors and stakeholders. The medical technology company, known for its innovative approach to diagnosing neurological conditions, plans to report its financial results for the fourth quarter and full year of 2024 after trading hours on February 25, 2025.
Anticipated Conference Call for Investors
On that same date, CeriBell's management will conduct a conference call meant to discuss the upcoming financial results in detail. This call is scheduled to commence at 1:30 PM PT / 4:30 PM ET. Participants interested in joining can dial (800) 715-9871 for domestic calls, or (646) 307-1963 for international connections. To enhance the experience, an access code of 3782735 will be required to join.
Exploring CeriBell's Impactful Technology
CeriBell is at the forefront of medical technology, particularly through its revolutionary Ceribell System. This state-of-the-art, point-of-care electroencephalography (EEG) platform addresses the critical needs associated with seizure diagnosis and monitoring. By leveraging proprietary, portable hardware along with advanced artificial intelligence algorithms, the Ceribell System offers rapid diagnosis and continuous assessment, ensuring timely and effective patient care in acute settings.
FDA Clearance and Its Implications
The Ceribell System is noteworthy not only for its cutting-edge technology but also because it holds FDA 510(k) clearance specifically for indicating suspected seizure activity. This achievement underscores the system's reliability and efficacy, leading to its adoption in various emergency and intensive care units across the United States.
CeriBell's Vision and Commitment
Headquartered in Sunnyvale, California, CeriBell remains dedicated to advancing medical technology that enhances the lives of patients suffering from serious neurological conditions. As we approach the financial results announcement, the company is on a path of innovation and growth, striving to meet the ever-evolving demands in the healthcare industry.
Investor and Media Inquiries
CeriBell values communication with its stakeholders and encourages inquiries for further information. For investor-related questions, individuals can reach out to Brian Johnston or Laine Morgan at the Gilmartin Group via email at Investors@ceribell.com. Media inquiries can be directed to Corrie Rose at Press@ceribell.com.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The call will provide insights into CeriBell's financial results for the fourth quarter and full year of 2024, along with discussions on the company's future strategies.
How does the Ceribell System work?
The Ceribell System utilizes portable EEG technology combined with AI algorithms, allowing for quick diagnosis and continuous monitoring of neurological conditions.
Is Ceribell publicly traded?
Yes, CeriBell is publicly traded on Nasdaq under the ticker symbol CBLL.
Where is CeriBell headquartered?
CeriBell is located in Sunnyvale, California.
How can investors get more information about CeriBell?
Investors can visit the CeriBell website or contact the investor relations team through the provided email addresses.
